The US FDA is developing a scientifically rigorous answer to the growing demand from politicians for the agency to conduct unannounced surveillance inspections abroad like it did domestically before the pandemic.
The FDA is relying on a statistical model to conduct a controlled case study of announced versus unannounced inspections, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?